Research Faculty

Eva Guinan, MD

Department Hematology/Oncology Eva Guinan, MD- Hematology/Oncology at Children's Hospital Boston
Hospital Title: Associate in Medicine
Academic Title: Associate Professor of Pediatrics
Phone: 617-632-4932
Fax: 617-632-3770
Email: Eva Guinan
Location: Dana-Farber Cancer Institute
44 Binney Street
Boston MA 02115

Research Overview

Eva Guinan's research focuses on overcoming problems related to allogenicity in transplantation, decreasing treatment related toxicity, and managing bone marrow failure syndromes. She also works with Harvard University collaborators on ways to spur more innovative translational research.

Allogeneic transplantation is limited, in large part, by the ability to find donors of suitable histocompatibility. Global immunosuppression has been an incomplete and highly toxic approach to this problem. Current understanding of T cell activation suggests that blocking B7-CD28 interactions of the costimulatory pathway for human T helper cells may provide an innovative and effective way of producing antigen-specific T cell hyporesponsiveness. Guinan and colleagues are applying these various strategies to the transplant setting.

Another area of active investigation is the development of novel agents for prevention or treatment of treatment-related toxicity.

About Eva Guinan

Eva Guinan received her MD from Harvard Medical School. She completed an internship and residency at Children's Hospital Boston and a fellowship at Children's Hospital/Dana Farber Cancer Institute.

Dr. Guinan received the Clare and Richard Morse Research Award, 2000 the Clinical Translational Scientist Award, Burroughs Wellcome, 1999 and the Distinguished Service Award of the Fanconi Anemia Research Foundation in 2009.

Key Publications

  • Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure: response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343.
     
  • Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anemia in children. Br J Haem 2007; 136(4): 549-64.
     
  • Davies JK, Nadler LM, Guinan EC. Expansion of allospecific regulatory T cells after anergized mismatched bone marrow transplantation. Sci Transl Med 2009; 1(1): 1ra3.
     
  • Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, McDonald GB, Guinan EC. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multi-center, randomized, dose-finding trial. Biol Blood Marrow Transplant (in press).